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(57) ABSTRACT
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portable medical diagnostic apparatus for analyzing a
sample body fluid (liquid and/or gas): (1) a mechanism to
capture airborne microdroplets and to separate the body fluid
into a first fluid component (primarily gas) and a second
fluid component (primarily liquid); (2) a volatilizer to con-
vert a portion of the second fluid component into a third fluid
component that is primarily a gas; (3) a functionalized
nanostructure (NS) array configured to receive, identify, and
estimate concentration of at least one constituent in the first
and/or third fluid components; (4) a miniaturized differential
mobility spectrometer (DMS) module; and (5) a biomarker
sensor, to detect volatile and non-volatile molecules in a
sample fluid, which may contain one or more components of
blood, breath, perspiration, saliva, and urine.
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Provide Nanostructure (NS) sub-arrays (n=1,...,N; N>_2) of electrically 
41responsive CNSs, with each sub-array being either non-functionalized or
functionalized are a different chemical or chemical process.
Provide two or more measurements EPV(n;meas,t,0), where all specific
chemical components are absent.
Provide calibration coefficients for each of K specified gas components
(k=1 .... K; Kz2), corresponding to linear terms KK1 quadratic terms (KK,)2
in a gas concentration value KK, and cross product terms (1KKj)(KK2) of
degree 2 for distinct gas components (k1 =k2)
Expose each sub-array to a sample gas, which may have at least one
unknown gas component having an unknown gas concentration value.
Provide or Measure EPV(n;meas;t) or AEPV(n;meas;t) for each
sub-array n.
Compute a weighted error sum E(LKK}), using the measured EPV
X 
change value AEPV(n;meas;t) and the calibration coefficients, where
the concentration value K, are not specified.
Minimize the error sum e({KK}) with respect to choices of each of the
concentration values KK = KK (min).
From From
step step +
58 54 To Step 48
FIG. 3A
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From step 47
48
To step 46
NO YES 49Is KK(min) <_ KK(thr1)? thr1
X
Set KK(min)=0
50
Specified component is likely present in sample gas (optional)
51
Estimate error function ({KKi=KK1(min);KK2=KK2(min)};K) numerically
54,55 NO Is S(min) 
<_ E(thr2)? YES 53 thr2
X
Minimum solution KK(min) is not Specified components are likely present
approximately correct and/or at in sample gas with estimate
14 least one important component is concentration valve(s) K,~(min)(k=1 .... K)
not included as a specified
Determine Kk(min;t) at two or more spaced apart times, t=t1, t2,..., and
X compare the corresponding concentration values Kk(min;t) with each other
for k fixed (optional)
To Step 57
FIG. 3B
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To step 42
From step 56
Estimate Asymptotic concentration value K,f(min;asymp) For K Fixed
RE;
NO YES
XKK(min;asymp) > KK(thr3)?
issue alarm signal for
specified component K
(optional)
FIG. 3C
61
FIG. 4
57
59
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PORTABLE MEDICAL DIAGNOSIS
INSTRUMENT
ORIGIN OF THE INVENTION
The invention described herein was made, in part, by
employees of the United States Government and may be
manufactured and used by and for the Government of the
United States for governmental purposes without the pay-
ment of any royalties thereon or therefore.
FIELD OF THE INVENTION
This invention relates to measurement and testing of a
chemical compound, provided from a test subject's body,
which may contain one or more biomedical markers indi-
cating presence of a medical condition.
BACKGROUND OF THE INVENTION
Extended human exploration missions, such as those
planned for Mars and other nearby planetary bodies, will
require improved technologies for medical diagnosis and
corresponding medical intervention capabilities, because of
mission duration (measured in years or decades), distance
from the Earth, and the environmental risks involved. Seri-
ous health problems that develop on such missions may
interfere with mission objectives and could produce mission
failure, if capabilities for prompt diagnoses and intervention
are not available.
For such missions, performance of rigorous pre-flight
medical screening may minimize the risk of serious diseases
and injuries. However, such screening cannot eliminate the
risk that a serious health condition or injury will occur.
Occurrence of known and unknown environmental hazards
confronted in space, including but not limited to radiation
and loss of bone function in a microgravity environment,
cannot be reliably predicted. Medical diagnosis on a future
deep space mission (e.g., to Mars and return) must be
autonomous and self-sufficient, because of the great distance
from an origin on Earth and from interactive health care.
What is needed is an autonomous medical system that
anticipates and provides means for diagnosing substantially
all serious medical conditions that may arise on a well
defined mission. Preferably, the medical system should
provide sufficient flexibility that the system can be modified
to handle other medical conditions that were not originally
anticipated.
SUMMARY OF THE INVENTION
These needs are met by embodiments of the invention,
which provides an integrated combination of instruments
that receive and analyze different body fluids (e.g., blood,
breath, perspiration, saliva and/or urine) from a test subject
to estimate one or more medical conditions that may be
present in the subject. The instruments that are integrated, in
various combinations, comprise the following: (1) a con-
denser surface that receives a body fluid; (2) an array of
functionalized nanostructures (NSs, for example, compris-
ing carbon) that receive the first fluid component, measure
changes in one or more electrical parameter values AEPV
after exposure of the NS array to the subject's breath or other
gases and vapors, and estimate specified components and
corresponding concentration values that are present in the
first fluid component; (3) a volatilizer (optional) that
receives the second fluid component and converts this
2
component partly into gases and vapors and microdroplets;
(4) a differential mobility spectrometer (DMS) that receives
an ionized portion of the first and/or second fluid compo-
nents and applies an RE asymmetric electrical field and a
5 compensating electrical field (dc) to transport the chemical
component(s) along a longitudinal channel, and to thereby
discriminate between ions of different composition; and (5)
a biomarker analyzer (optional) that may be a capillary
action biomarker analyzer (CABA) mechanism for moni-
10 toring presence or absence of one or more target analytes;
and/or may be a centrifuge assisted bead sedimentation
biomarker analyzer (CASBA) for monitoring presence or
absence of one or more target analytes. Each of these
15 instruments provides a different and partly independent
physical or chemical perspective on a body fluid that is being
tested.
BRIEF DESCRIPTION OF THE DRAWINGS
20
FIG. 1 schematically illustrates embodiments of the
invention.
FIG. 2 schematically illustrates an NS array.
FIG. 3A-3C show a flowchart illustrating operation of an
25 NS array.
FIG. 4 illustrates operation of a DMS instrument.
FIG. 5 illustrates a mechanism using controlled capillary
flow to estimate the presence or absence of a specified
substance (analyte) of interest.
30 FIG. 6 illustrates pathways for detection of analytes.
DESCRIPTION OF THE INVENTION
FIG. 1 schematically illustrates embodiments of an inte-
35 grated system 11 that can be used to measure and analyze
one or more body fluid components (e.g., blood count,
breath, perspiration, saliva and/or urine) of a subject, to test
for presence of one, two or more medical conditions present
in the subject. A body fluid is received by a condenser
40 surface 12 and is separated into a first fluid component that
is primarily a gas, and a second fluid component that is
primarily a liquid. An example of a condenser surface is
disclosed in Published U.S. Patent Application 2014/
0358023. The condenser surface is applied here only to
45 processing breath.
A portion of the first fluid component (primarily gas
and/or vapor) is received by an array 13 of nanostructures
(NSs) and associated NS readout mechanism 14, illustrated
in FIGS. 1 and 2, that are preferably functionalized to
5o discriminate between at least first and second specified
chemical components, based on measured values in at least
one electrical parameter change value AEPV. The electrical
parameter change value AEPV comprises change in electri-
cal resistance, electrical conductance, electrical impedance,
55 electrical capacitance, electrical inductance, voltage differ-
ence or electrical current. The NS array may be functional-
ized by loading (e.g., doping or impregnating or coating a
portion or all of the NSs with a selected dopant or impreg-
nation or coating substance, or by processing the NSs with
6o another suitable procedure. Relevant results from the NS
analysis of the first fluid component are received, stored
and/or displayed by the readout mechanism 14.
A portion or all of the first fluid component is received by
a differential mobility spectrometer (DMS) 16 and associ-
65 ated readout mechanism 17 in FIG. 1 that applies a vertical
electrical field, which is asymmetric in time, to discriminate
between ions with different molecular compositions, by
US 9,824,870 B1
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capturing some ions on side plate electrodes and permitting
other ions to pass through and exit from a DMS drift tube.
A portion of the second fluid component is received by a
heater/volatilizer mechanism 15 (optional) in FIG. 1 that
volatilizes a portion of the second fluid component into a
third fluid component (vapor or gas), with the remainder
being a fourth fluid component. The volatilized portion
(third fluid component) and the first fluid component are
received by the DMS 16. The DMS 16 thus separately
interrogates the first and second fluid components, and
relevant results from the DMS analyses are received, stored
and/or displayed by a DMS readout mechanism 17.
The fourth fluid component (primarily liquid) is received
by a biomarker analyzer 18 and associated biomarker ana-
lyzer readout mechanism 19 (optional). The biomarker ana-
lyzer 18 may be a centrifuge Assisted Biomarker Analyzer
(CASBA) and/or may be a Capillary Action Biomarker
Analyzer (CABA), which are discussed in the following.
The CASBA mechanism and/or the CABA mechanism
includes a tunable, narrow wavelength range, fluorescence
excitation light source and corresponding fluorescence esti-
mator that senses the range of fluorescence wavelengths
produced and estimates the corresponding intensity(ies) of
the output wavelength(s).
Each of the NS array 13, the DMS 16 and the biomarker
analyzer 18 has a readout mechanism, 14, 17 and 19,
respectively, that provides at least one of a numerical
readout and/or a visual readout of relevant Z/m data.
The first fluid component may include gases from breath,
from perspiration, from saliva, and from urine, among
others. The second fluid component may include liquids
from blood, from perspiration, from saliva and from urine,
among others. As noted, the condenser surface is applied
only to process breath.
FIG. 2 schematically illustrates a measurement system 31
that provides functionalized nanostructures ("NSs") as part
of the invention. The measurement system 31 includes: a
substrate 32; an appropriate catalyst underlayer 33 (op-
tional); a sequence of distinct sub-arrays 34-n (n=1, ... , N;
N23) of NSs deposited or grown on the substrate 32; a
selected "loading" (doping, impregnation, coating, non-
functionalized, etc.) 35-n of an NS sub-array 34-n; a source
36 of a sample gas or vapor to be interrogated; an EPV
measurement and readout mechanism 37 for measuring,
analyzing, storing and/or displaying one or more electrical
parameter values EPV(n;meas.t) or EPV change values
AEPV(n;meas;t) at each of the N NS sub-arrays, before and
after exposure of that sub-array to the sample gas; a mobile
communication mechanism 38 (optional), including a com-
puter that is programmed to receive the sequence of mea-
sured electrical parameter values, EPV(n;meas;t), or EPV
change values, AEPV(n;meas;t), to compare the measured
values with corresponding reference values EPV(n;ref), and
to estimate whether a specified chemical or component is
likely present in the sample gas; a most probable concen-
tration value (if the specified component is likely present in
non-negligible concentration); and a system refresh mecha-
nism 39 (optional), to refresh and reset the NS sub-arrays for
subsequent measurements, in a time interval, preferably with
length no more than about 15-30 sec. Each NS sub-array
34-n may consist of a single NS or may include two or more
NS s with the same functionalization. Two different NS
sub-arrays, 34-n1 and 34-n2, may have the same number, or
a different number, of NSs. For some sample gases, the
response time for detection may be no more than about 2-5
sec; and/or the minimum detection value may be as low as
5 ppbv (parts per billion by volume; e.g., NO2, with a
4
detection limit of about 4.6 ppbv at T=25° C.). Response
time for detection of other gases at a detection limit (mini-
mum measurable concentration value) may be greater.
Embodiments of the system 31 are discussed in more detail
5 in U.S. Pat. Nos. 7,801,687 and 8,000,903, issued to ling Li
et al and incorporated by reference herein.
Nanostructure Measurement Procedure.
Up to 32 individually functionalized NS channels in the
system 31 were initially tested and confirmed to work as
io expected. This number has been increased to an array of 64
channels (1 cmxI cm size), and will be increased further as
the perceived need increases, limited only by considerations
such as chip size, interconnections, and signal-to-noise ratio.
An array of 32 NS channels has been reduced in size to that
15 of a postage stamp, which can fit into, and provide connec-
tions to, a mobile communication system (optional; dis-
closed in U.S. patent application Ser. No. 13/896,271, incor-
porated herein by reference).
The surface area per unit mass for the NS is very high, up
20 to about 1580 m2/gm in one embodiment, so that the EPV
change value AEPV is quite sensitive to presence of even a
small amount of a specified chemical or component. For
example, presence of nitrogen dioxide (NO2) at a concen-
tration of 4.6 ppbv has been detected using one NS sub-
25 array. With an appropriate choice of differently functional-
ized NSs, the NS sub-array can collectively distinguish
between presence of two or more different specified com-
ponents and can provide an estimate of most probable
concentration value, for each component that is present
3o above a detection threshold concentration. Thus far, we have
tested our functionalized NS array on more than 15 different
specified components, including ammonia (NH3), nitrogen
dioxide (NO2), hydrogen chloride (HCl), chlorine (C12),
hydrogen cyanide (HCN), hydrogen peroxide (H2O2),
35 hydrazine (N2H4)1 methane (CH4), benzene (C,H6), acetone
((CH3)2CO), formaldehyde (CH20), toluene (C,H5(CH3))1
dinitrotoluene (DNT), and some nerve agents and simulants
thereof, such as satin, soman, and dimethyl methylphospho-
nate (DMMP). As the number of different specified compo-
4o nents being tested increases, the required number of sepa-
rately functionalized NSs also increases. The sensors
constructed using the functionalized NSs are robust, long
lasting (at least three years lifetime), will operate in the
presence of high intensity vibrations, and the measured
45 values can be compensated for varying temperature, varying
humidity and varying pressure.
An NS array or sub-array can be recycled or refreshed,
after its use for a particular gas, by at least two methods: (1)
local heating of the NS array to temperatures of about 120°
50 C. for about 10-15 min and/or (2) irradiation of the NS array
with ultraviolet-emitting LEDs (e.g., with wavelengths in a
selected range, such as X-254-256 run, for several seconds.
The particular electrical parameter change value AEPV
(n;meas;t), measured for each of the functionalized or non-
55 functionalized sensor sub-arrays, may be electrical resis-
tance, electrical conductance, electrical capacitance,
electrical inductance, voltage difference, electrical current,
or some other relevant, measurable electrical value. For
electrical current, for example, the change values AEPV(n;
60 meas;t) are often measured in µAmps or in mAmps.
FIGS. 3A-3C is a flow chart illustrating a suitable pro-
cedure for practicing the invention using the system 31.
Step 41: Provide N nanostructure ("NS") sub-arrays,
numbered n=1, ... , N (N>_2), on a substrate, where each NS
65 sub-array is either not functionalized or is functionalized
with a selected functionalizing substance or process, where
each NS sub-array comprises at least first and second
US 9,824,870 B1
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interdigitated electrodes, with the first and second electrodes
being connected at a first end to at least one of (i) a
controllable voltage source and (ii) a controllable current
source, and with the first and second electrodes being
connected in an electrical path to each other through one or
more of the NS sub-arrays.
Step 42: Provide at least one measurement (preferably, at
least two measurements) of an electrical property value
EPV(n;meas;t;0) for n=1, . . . , N, where all specified
components are absent, but other ambient components may
be present, where an EPV value, measured at a particular
sensor sub-array (n) and corresponding to a single specified
component (ml) is approximated by a constitutive relation,
EPV(n;kl;meas)-ao(n)+bkl(n)Kkl+Cl,l(n)Kkl2, (1)
where Kk1 is a value of concentration of the specified
component kl and ao(n) represents EPV response where no
specified component or analyte is present. Where two or
more specified components, numbers k=k1 and k2, are
present, an expanded constitutive relation for the combined
specified components is used,
EPV(n; k1,k2;meas)-a0(n)+b 1(n)Kk1+b2(n)Kk2+C1 1(n)
Kk12+C2,2(n)K722+dj,2(n)Kk1K7,2, (2)
where d1 2(n) is a cross product term associated with the
concentration cross product, Kk,Kk2• (Kk1~'Kk2)
Step 43: Provide calibration coefficients ao(n) (optional),
bk(n), ck,k(n) and dkl,k2(n), for the sub-array number n-
1, 2, ... , N for the K specified components, numbered k=kl,
k2=1, ... , K, with kl;-k2 and K>_1 (preferably K>_2). The
calibration coefficient ao(n) is associated with the measured
value EPV(n;meas;t;0) for n=1, ... , N. Where one works
with a measured EPV change value, defined as
4EPV(n;meas;t) EPV(n;meas;t)-EPV(n;meas;t,-0), (3)
the calibration coefficient ao(n) need not be used in modeling
4EPV behavior for a particular specified component.
For arbitrary concentration values Kk of one or two speci-
fied components (k=k1, k2=1, ... , K; K=1 or 2), it is
assumed that the measured change value 4EPV(n;meas;t)
for a given sub-array (n) can be expressed or approximately
modeled as a nonlinear combination of the concentrations K1
and K2,
4EPV(n; kl,k2;model;t)-b 1(n)Kk1+b2(n)Kk2+C1 1(n)
(Kkl)2
+C2,2(n)(Kk2) 
+2dj,2(n)(Kkl)(K7,2), (4)
for (postulated) presence of two specified components with
the associated concentrations, K1 and K21 where n refers to
the particular NS sub-array. Where a value EPV(n;meas;t) is
used, the coefficient ao(n)-EPV(n;meas;t;0) is also included
in the right hand sum in Eq. (2). Inclusion of a cross-product
term, d1,2(n)(Kj(K2), accounts for interaction of at least two
distinct components. The calibration coefficients, ao, b, ek,k
and dkl,k2 (k=k1 or k2), are estimated or determined experi-
mentally for a single specified component or pairs of speci-
fied components. Optionally, the NS array may include
sensors for one or more environmental values, such as
temperature, humidity and/or pressure. The calibration coef-
ficients, ao, bkv bk2l Ckl,kv ck2,k2 and dkl,k2, in Eq. (4), can
be compensated for variation of one or more of these
environmental variables, using, for example, techniques
disclosed in U.S. Pat. No. 8,000,903, issued to ling Li and
incorporated herein by reference.
Where only one specified component (e.g., Kkj is postu-
lated to be present, the coefficients bk2(n), eke k2(n) and
d,, k2(n) are preferably set equal to 0. The nonlinear com-
bination of concentration values in Eq. (2) can be extended
to presence of K (>_2) components, with an increase in the
experiments needed to determine the total number, (K+1)
(K+2)/2, of calibration coefficients needed, but the compu-
6
tations are much more complex. For K=1 and K=2, the
maximum numbers of calibration coefficients required are 3
and 6, respectively.
Step 44: Expose the NS sub-arrays for a selected time
5 interval to a sample gas, which may contain, but need not
contain, one or more of the specified components, where the
sample gas is to be examined for presence or absence of each
of K specified components, numbered k=1, ... , K.
Step 45: Provide or measure electrical property change
10 values 4EPV(n;meas;t), defined in Eq. (3), between the
first and second electrodes in the NS sub-array number
n=1, ... , N, as a result of exposure of the NS sub-array
number n to the sample gas, where each EPV change value,
4EPV(n;meas;t), is drawn from the group of change values
15 consisting of electrical current, voltage difference, resis-
tance, impedance, conductance and capacitance, measured
between the first and second electrodes in the NS sub-array
number n.
20 Step 46: For K>_2, form a non-negative error sum
[
N (5)
-041, Kk21; K)= ,WnlDEPV(n;meas;t)- DEPV(n;model;t)jp,
-1
25
from weighted differences between the measured change
values 4EPV(n;meas;t) and an estimate of the modeled EPV
change values computed using the calibration coefficients,
30 with specified gas component concentrations K,((k=1, ... ,
K) that are not yet known. Here, {w } are non-negative
weight coefficients, at least one being positive, and p is a
selected positive number (e.g., p=1 or 1.62 or 2 or V17 or any
other rational or non-rational number).
35 Step 47: Minimize the error function sum for choices of
each of the concentration values, Kk1 and Kk2, to obtain
estimates of minimum-solution concentration values, Kk Kk
(min) (k=k1, k2) that together provide a minimum numerical
value Efrain) for the error sum EQKk1,Kk2};K) in Eq. (5).
40 Step 48: Where an estimated minimum-solution concen-
tration value Kk(min) is no greater than a selected threshold
concentration value Kk(thrl) for the specified gas compo-
nent, k, in step 48, interpret this condition as indicating that
the specified component k is present in the sample gas, if at
45 all, in a negligible concentration (Kk(min)=0).
Step 49: Set the concentration value Kk equal to 0 (op-
tional), if the condition in step 48 is satisfied for a particular
specified component number k.
Step 50: Where an estimated minimum-solution concen-
50 tration value Kk(min) is greater than the selected threshold
concentration value Kk(thrl) for the specified gas component
k, interpret this condition as indicating that the specified
component k is present in the sample gas with an estimated
concentration Kk(min), (optional).
55 Step 51: Numerically evaluate or estimate the error func-
tion, E(min)_EQKk1=Kk1(min); Kkz Kk2(min)};K), for each
concentration value K equal to its minimum-solution value,
Kk Kjmin).
Step 52: Compare the minimum error value EQKkl=Kk1
60 (min); Kk2=Kk2(min)};K)_E(min) to a selected threshold
error value, E(thr2).
Step 53: Where the minimum error value EQKkl=Kk1
(min); Kk2=Kk2(min)};K) is no greater than a selected error
threshold E(thr2), interpret this condition as indicating that
65 the specified components are likely to be present in the
sample gas, with concentration values approximately equal
to the minimum-solution values Kk(min).
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Step 54: Where the minimum error value E({Kkl—K,,
(min); Kk2=Kk2(min)};K) is greater than the selected error
threshold value e(thr2), interpret this condition as indicating
that either (i) the minimum-solution concentration value is
not approximately correct for at least one specified sample 5
gas component (k=1, . . . , K), and/or (ii) at least one
important gas component that is present is not included as a
specified component in the sample components.
Step 55: Where the query in step 54 is answered "yes,"
include at least one additional gas component in the list of io
specified gas components and include additional calibration
coefficients for one or more additional sample gas compo-
nents in the specified components list, for each of the arrays
n=1, ... , N, and return to step 43 (optional).
Step 56: Estimate the minimum-solution concentration 15
values, K=Kk(min;t), at two, three or more spaced apart
measurement times, t=t1, t2(>tl), O(>t2), etc., and compare
the corresponding concentration values, Kk(min) (k fixed; t
variable), with each other for the measurement times.
Step 57: Where the corresponding minimum-solution 20
concentration values Kk(min;t) are substantially different
from each other for two or more spaced apart measurement
times (e.g., the absolute value of the difference for fixed k is
greater than a positive threshold difference), estimate an
asymptotic minimum-solution concentration value, Kk Kk 25
(min;asymp) for that specified chemical (optional), using a
first order or second order chemical reaction model, and
(optionally) make this asymptote available for at least one
recipient. Preferably, an asymptotic estimate, Kk Kk(min;
asymp), is promptly estimated, where the specified compo- 30
nent and its concentration value may be a concern for human
health or safety.
Step 58: The system determines if the predicted asymp-
totic concentration value, Kk(min;asymp), or the present
concentration value Kk(min;t), is at least equal to a selected 35
alarm-threshold concentration value Kk(thr3).
Step 59: When the answer to the query in step 58 is "yes,"
the system promptly issues an alarm signal to advise inter-
ested users of the system that the present or predicted
asymptotic concentration value for at least one gas of 40
concern is, or will soon be, above the alarm-threshold
concentration value, Kk(thr3).
Optionally, the system compares the minimum-solution
concentration value, Kk(min), with the threshold concentra-
tion value Kk(thr3) for first and second sampling times, and 45
monotonically decreases a separation time between the first
and second sampling times when (i) the minimum-solution
concentration value is less than the threshold concentration
value, Kk(thr3), and (ii) the minimum-solution concentration
value appears to asymptotically approach, or to exceed, the 50
threshold concentration value Kk(thr3). This provides a finer
measure of approach of Kk(min;t) to an asymptotic value.
For a choice of K=1 specified component, no cross
product terms are present in a constitutive relation, and the
calibration coefficients ao(n), b1(n) and c,,,(n) may be deter- 55
mined by a quadratic regression process. Assume that a
collection of measurements EPV(n;meas;Kk;t) (k1, ... , K;
K>_2) is provided, with corresponding known concentration
values Kk). An error function
60
£(ao(n), bkI (n), ekl,kI (n)) _ (6)
K1~
LI 
Iao (n) + b1 (n)Kk1 + e1,1(n)Kkl — EPVn;meas;KkI ;t12
k1=1 65
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is minimized with respect to choices of the calibration
coefficients ao(n), b1(n) and c1 ,(n). This yields three
coupled equations in these coefficients:
~K (7A)
L I ao (n) + b1(n)Kk1 + C1 1(n)Kk1 — EPV (n;meas; Kk1 ;t)1{ 11 =0,
k1=1
~K (7B)
L {ao(n) + b1 (n)Kkl + el,l (n)Kkl — EPV(n;meas; Kkl;t)}{Kkl1 = 0,
k1=1
~K (7C)
L Iao(n) + b1 (n)Kk1 + e1,1 (n)Kkl — EPV(n;meas; Kk1;t)1{Kk1 } = 0,
k1=1
whose joint solutions Kk1 for each NS array (n) can be
estimated.
Inclusion of additional terms in Eq. (2), beyond second
degree in the concentration values Kk, is possible but tedious
and requires additional experiments and reference measure-
ments. The model adopted in Eq. (2) includes the lowest
order effects of linear and quadratic dependences upon
individual concentration values Kk and of lowest order cross
product terms, such as (Kkl)(Kk2). Preferably, functionaliza-
tions for the different NS sub-arrays are chosen so that no
two sets of calibration coefficients, (ao(nl), bk(nl), ck,k(nl),
dkl,k3)(nl)) and (ao(n2), bk2, (n2), ck2,k2(n2), dk2,k4)(n2)), are
approximately proportional to each other for nl;-n2.
Given N sub-arrays of NS sensors and a set of K specified
components, numbered k1, ... , K (K1, 2, ... )), the
measured EPV change data for the sensors can be pre-
processed in order to identify more clearly which function-
alized NS sensor sub-arrays are more sensitive to presence
of a particular specified component. In a first embodiment,
the sub-array is exposed to a selected component (k) of a gas
of concern (e.g., liquid explosive, toxin, poison or nerve
agent), for example, CO2, NH3, NO2, C12, HCl, HCN, H2O21
N2H4 (hydrazine), CH4 (methane), C,H5(CH3) (toluene),
C,H6 (benzene), CHACO (acetone), DNT (dinitrotoluene,
CH2O (formaldehyde), DMMP (dimethyl methylphospho-
nate), sarin, soman and/or other gases, at a selected sequence
of two or more concentration values {Kk(q)}q (q=1, ... , Q
with 1 <_Q<_N) of Q different, specified concentration values,
and a reference measurement value, EPV(n; Kk(q);ref) (n1,
2, ... , N), is recorded for each sensor sub-array n and for
each known concentration Kk(q) of a reference gas contain-
ing a specified component (k). Some of these gases appear
simultaneously, as separate components and in an assembled
molecule(s), so that, whenever a characteristic component is
found, presence of the other components and of the corre-
sponding assembled molecule should also be queried.
Differential Mobility Spectrometer.
FIG. 4 schematically illustrates operation of one embodi-
ment of a differential mobility spectrometer (DMS) 61 for
use in the invention. The diagnostic device 61 comprises a
drift tube, an ionization source and a source of ions at a first
end of the drift tube; and first and second ion detectors for
respective negatively charged and positively charged ions
located at a second end of the drift tube. Optionally, the
device also includes one or more sources of a compensating
electrical (CE) field that can be individually or collectively
varied with time to discriminate between ions with different
mass-to-charge ratios m/Z, different sizes and different
shapes or collision cross-sections, collectively referred to as
differential mobility parameters The device uses mobility
differences of chemicals in high strength, asymmetric elec-
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trical fields to separate and provide identifying information
for the compounds. Typically, the device has a longitudinal
length of 10-100 cm, a diameter of 5-10 mm, and an applied
electrical field strength IEl of 5-300 Volts/mm, but may be
larger or smaller. Here, the device is miniaturized.
Use of the device for breath analysis is discussed in the
following disclosures, which are incorporated by reference
herein: M. Schivo et al, Jour. Of Breath Research 7(1):
017113 doi: 10.1088/1752-7155/7/1/017113; C. E. Davis et
al, IEEE Sensors Jour., Special Issue, "Sensors For Breath
Analysis" vol. 10, pp. 114-122,2010; C. E. Davis et al, IEEE
Sensors Jour., Special Issue, "Sensors For Breath Analysis"
10(1) 3-6; M. Molina et al, Analytica Chimica Acta, vol.
628, pp. 155-161, 2008.
Capillary Action Biomarker Analyzer (CABA).
A Capillary Action Biomarker Analyzer (CABA) system
71, illustrated in FIG. 5, uses microfluidic flow of captured
and detected antibodies in controllable capillaries to isolate
and identify biological substances of concern that may be
presented in certain medical conditions, using a modified
ELISA procedure. A microfluidic transport and display card
and reader is provided with a central entry port region 72
that receives a liquid sample LS, usually a few drops. The
entry port 72 is connected to each of R separate channels
73-r (r1, ... , R) that serve as entry channels for the sample.
The liquid sample LS may include a target substance TS-r,
whose presence or absence is to be assessed.
A portion of the sample LS in channel 73-r moves into a
mixing chamber 75-r that contains at least one capture
antibody CAB-r that is sensitive to, and binds with, the
target substance TS-r. If the target substance TS-r is con-
tained in the sample LS, some molecules of the capture
antibody CAB-r and the target substance TS-r will combine
as a plurality of mobile CAB-r/TS-r complexes in the
mixing chamber 75-r and/or in a serpentine capillary action
channel 76-r that receives and transports output from the
mixing chamber 75-r. A detection and viewing chamber 77-r
contains detection antibody molecules DAB-r that are bound
or otherwise attached to a substrate that is part of the
chamber 77-r. The detection and viewing chamber 77-r
receives the output CAB-r/TS-r complexes from the serpen-
tine capillary action channel 76-r.
The detection antibodies DAB-r have been conjugated
with a photosensitive labeling agent, such as a fluorescent
molecule or colorimetric label; and some of the mobile
CAB-r/TS-r complexes, if present, will combine with the
immobilized DAB-r antibodies and form an immobilized,
photosensitive-labeled, CAB-r/TS-r/DAB-r complex. The
contents of the detection and viewing chamber 77-r that are
not immobilized are carefully washed away. Only the immo-
bilized CAB-r/TS-r/DAB-r complexes, if any, remain in the
detection and viewing chamber 77-r.
The serpentine capillary action channel 76-r, the detection
and viewing chamber 77-r and a wicking pad or pump 78-r
(optional) form a transport channel 79-r for the CAB-r/TS-r
complex. After the CAB-r/TS-r/DAB-r complex has formed
and become immobilized in the detection and viewing
chamber 77-r, a light source 80-r, having a narrow wave-
length range (alr<~<~Zr) is activated and illuminates the
contents of the detection and viewing chamber 77-r.
When and only when, upon such illumination, some
molecules in the CAB-r/TS-r/DAB-r complex in the viewing
and detection chamber 77-r are activated and emit fluores-
cence or other radiation in an expected narrow wavelength
range and with an intensity at least equal to a selected
threshold intensity, the system concludes that the target
substance TS-r is present in the liquid sample. When, in
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response to such illumination, the contents of the detection
and viewing chamber 77-r do not emit radiation in the
expected wavelength range, or appear with a radiation
intensity below the selected threshold intensity, the system
5 concludes that the target substance TS-r is not present in the
liquid sample LS. In this CABA mechanism, after the
unknown sample and the capture antibody CAB-r combine
as a complex, this complex is mobile, not localized. Subse-
quent interaction of this complex with an immobilized
io detection antibody DAB-r causes immobilization of the
CAB-r/TS-r/DAB-r complex, for purposes of detection.
The contents of the detection and viewing chamber 77-r
are carefully washed. The molecules of liquid sample LS
and capture antibody CAB-r that are not immobilized in the
15 detection and viewing chamber 77-r, are removed from the
system.
The system 71 can be configured to interrogate the liquid
sample LS with light in each of R narrow, preferably
non-overlapping wavelength ranges, X1,,:5X:5 ,2,, (r=1, .... R;
20 R>_2), in order to confirm or refute the hypothesis that one
or more of the target substances TS-r(r=1, ... , R) is, or is
not, present in the liquid sample LS. If R separate channels
73-r are provided, presence of as many as R different target
substances can be simultaneously tested; or contemporane-
25 ous appearance of radiation for two or more distinct wave-
length ranges for the same biomarker can be sensed to
provide further confirmation of presence of the target sub-
stance TS-r.
Apart from a small amount of energy used in providing
30 the activation wavelength, no electrical power is required
here for this alternative. Rate of delivery of the CAB-r/TS-r
complex to the detection and viewing chamber 77-r, is partly
controlled by choices of effective diameter and effective
length of the transport channels 79-r.
35 Centrifuge Assisted Sedimentation Biomarker Analyzer
(CASBA).
Another procedure for analyzing composition and esti-
mating concentration of blood components uses a novel
sedimentation approach to conduct bead-based ELISA-type
40 sandwich immunoassays in a circular disk (CD)-based cen-
trifugal microfluidics device. The CD contains fluorescently
labeled "detection" antibodies in the sample-loading cham-
ber. The disk also contains density centrifugation media in
the separation zone. In one embodiment, a fluid such as
45 whole blood or saliva is loaded into the disk, using a
disposable plastic pipette or capillary tube and incubated for
a few minutes. The CD is spun to separate the beads from
unreacted reagents and sample. An optical detector reads the
fluorescent signal from the sediment beads. Multiple ana-
50 lytes can be detected in minutes from a single drop of fluid.
Advantages of the device sample analysis include the fol-
lowing: further miniaturization is available; sample-to-an-
swer procedure can be performed in less than 15 minutes;
high analytical sensitivity; and ability to multiplex, with 16
55 to 32 assays per CD. The analyzer does not require sample
preparation before the sample is loaded into the device so
that the device can be adapted for space applications.
Details of the approach are discussed in the following
articles, which are incorporated by reference herein: U. Y.
60 Schaff et al, Clinical Chem., vol. 57, pp 753-761, 2011; G.
Sommer et al, "Microfluidic Devices, Systems and Methods
for Quantifying Particles Using Centrifugal Force," U.S.
patent application Ser. No. 12/891,956, September 2010; G.
Sommer et al, "Devices, Systems and Method for Conduct-
65 ing Sandwich Assays Using Sedimentation,", U.S. patent
application Ser. No. 12/891,977, September 2010; G. Som-
mer et al, "Systems, Devices and Methods for Agglutination
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Assay," U.S. patent application Ser. No. 13/423,073, March
2012; G. Sommer et al, "Rapid Sensitive Detection &
Quantification of DNA in Clinical Samples," U.S. patent
application Ser. No. 13/423,008, March 2012; G. Sommer et
al, "Devices, Systems and Methods for Conducting Assays,"
U.S. patent application Ser. No. 13/423,050, September
2012; G. Sommer et al, "Quantitative Detection of Patho-
gens in Centrifugal Microfluidic Disks," U.S. Patent Appl.
61/673,373, July 2012.
An ELISA procedure is applied to sedimentation of
functionalized or sensitized particles, some of which may be
bound to a sample containing the target substance (e.g., an
antigen). The procedure is preferably performed in a density
medium in which the density p(part) of an individual sedi-
mentation particle is greater than the density p(medium) of
the density medium, which is greater than a density p(part-
sample;avg) of a combined (averaged) particle-sample com-
plex p(part-sample).
The mixture is preferably centrifuged to separate the
heavier particle-plus-complex from the lighter density
medium. Response of the labeled detection agent(s) is
analyzed, by photo-excitation of the detection label DL, to
confirm or refute the postulated presence of the target
substance TS bound on some or all of the sedimentation
particles. Photo-excitation will appear only where a detec-
tion label DL with a corresponding wavelength-activation
range is present; and if present, the signal intensity will be
approximately proportional to concentration of the target
substance TS. Using Stokes law, the sedimentation rate for
the particles is proportional to a difference between p(part)
and p(medium).
Pathways for Identification.
FIG. 6 illustrates some of the individual pathways for
identification and analysis of different chemicals, analytes
and/or antigens that are present in a sample. This charac-
terization focuses on a "carrier" and the most useful tech-
nologies for the target chemicals, analytes and/or antigens:
volatiles, small non-volatiles, blood analytes, blood cell
counts, breath, perspiration, saliva and urea. This character-
ization extends to pathways for perspiration and for urine
(urea is found in both, if the measurement is taken within
two hours of urine excretion), which may include additional
components analogous to the blood components found in
breath, in perspiration, in saliva, and/or in urine. As noted,
use of the condenser is limited to processing of breath.
The system 90 of pathways comprises one or more of the
following. A breath pathway module 91A receives volatiles
and small non-volatiles and passes this substanc(es) through
a first breath intermediary 91B that comprises a condenser,
an NS array and a DMS; and that passes this substanc(es)
through a second breath intermediary 91C that comprises an
NS array arranged to receive substances from a headspace
sampler.
Ablood pathway module 92A receives blood analytes and
blood cell counts and passes this substance(es) through a
first blood intermediary 92B that comprises a DMS and a
biomarker analyzer.
A saliva module 93A receives blood analytes and saliva
samples and passes this substance(es) through a first saliva
intermediary 93B that comprises a DMS, an NS array and a
biomarker analyzer; and that passes this substance(es)
through a second saliva intermediary 93C that comprises a
head space sampler and a NS array.
A urine and/or perspiration pathway module 94A
receives urine and/or perspiration volatiles and passes this
substance(es) through a first urine/perspiration intermediary
94B that comprises an NS array and a DMS; and that passes
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this substance(es) through a second urine/perspiration inter-
mediary 94C that comprises a head space sampler and a NS
array. The processed and/or interrogated substances are
further processed and/or stored and the relevant results read
5 out by one or more readout mechanisms 95.
Comparison of Medical Conditions.
The NS sensor array, illustrated in FIG. 2, and/or the DMS
module, illustrated in FIG. 4, and/or a biomarker analyzer,
illustrated in one embodiment in FIG. 5, may independently
10 indicate that a first medical condition and/or a second
medical condition, respectively, are present in the subject. It
may be instructive to compare attributes of the first and
second medical conditions, which may correspond to the
15 same medical condition or may correspond to different
medical conditions. Where the first and second medical
conditions are the same, or substantially the same, conflu-
ence of the first and second medical conditions may confirm
presence of this medical condition in the subject. Where one
20 of the two embodiments shown in FIGS. 2, 4 and 5 indicates
presence of a medical condition ("PMC") but the other
embodiment does not indicate presence of any medical
condition, the indicated presence of PMC may be accepted,
subject to confirmation by more focused analyses.
25 In some situations, the embodiments described in FIGS.
2, 4 and 5 may indicate presence of a first and presence of
a second medical condition, referred to as PMC 1 and PMC
2, respectively. Where at least one attribute in PMC 1 is
inconsistent with at least one attribute in PMC 2, this may
30 indicate that at most one of PMC 1 and PMC 2 is present,
and subsequent analysis should focus on confirmation or
refutation that each of PMC 1 and PMC 2 is present in the
subject. Where each primary (or most relevant) attribute of
PMC 1 is not inconsistent with each primary (or most
35 relevant) attribute of PMC 2, this may indicate that a single
medical condition, having at least one primary attribute from
PMC 1 and at least one primary attribute from PMC 2, is
present in the subject. Occurrence of this condition (first and
second attributes, not inconsistent with each other) may help
40 limit the search for presence of a single or primary medical
condition in the subject.
Suitable Sources for Samples.
Blood, considered as a sample, has four major compo-
nents: (1) erythrocytes (red blood cells, which lack a nucleus
45 and transport hemoglobin and oxygen from the lungs to all
living tissues in the body; produced from stem cells in the
bone marrow; viable for about four months); (2) leukocytes,
lymphocytes, granulocytes and macrophages (white blood
cells; first responders for the immune system, as part of the
5o human leukocyte antigen (HLA) system; seeks and destroys
alien proteins on bacteria, viruses and fungi; produced from
bone marrow stem cells and in the thymus gland; most are
viable for 18-36 hours); (3) platelets (thrombocytes; frag-
ments that lack a nucleus and provide clotting at a wound
55 site; 13 different clotting factors are identified; which also
fight infection by releasing proteins that destroy invading
bacteria; effectiveness varies with the time of day; viable for
9-10 days); and (4) plasma (transports red cells, white cells,
platelets, oxygen, nutrients, vitamins, electrolytes, metabo-
60 lism waste products, hormones, enzymes, antibodies, other
proteins, carbohydrates, and heat; produced from bone mar-
row stem cells). When blood of two persons is mixed
together, with different markers or antigens on the red cell
surfaces, these cells may agglutinate (clump together) or
65 burst, both undesirable reactions. When agglutination (clot-
ting) occurs, the blood mostly remains liquid (becomes
non-liquid)
US 9,824,870 B1
13
At present, 29 different human blood systems have been
identified, with one or more antigens (a total of more than
100) for each of these blood groups. Approximately 30,000,
000 possible HLA genotypes have been identified. HLA
incompatibility between donor and donee is a continuing
concern. Blood represents about 8 percent by weight of an
adult human (4.5-6 liters). Blood components, especially the
plasma, can be interrogated to identify the nutrients, elec-
trolytes, waste products, proteins and antigens present, and
their relative concentrations, to identify any medical condi-
tions of concern. Reference ranges (minimum to maximum)
for each of several substances can be established experi-
mentally for a target person, and the corresponding present
measurement can be compared with this reference range to
identify any anomalies. This comparative approach can also
be applied to compositions and concentrations of nutrients,
electrolytes and waste products (exhaled breath, perspira-
tion, saliva and urine). Blood components can be analyzed
using a DMS module.
In the process of breathing, a human will inhale about 78
percent nitrogen, 21 percent oxygen, and 1 percent trace
gases, such as Ar; and this person will normally exhale 78
percent nitrogen, 13.6-16 percent oxygen, 4-5.3 percent
CO2, 3-5 percent water vapor, and 1 percent trace gases (Ar,
H21 CO, ammonia, acetone, methanol, ethanol, etc.). The
relative ranges of 02 and CO2, before and after a breath is
taken, will vary the most, and the inhale/exhale changes in
these two substances should be compared with reference
ranges for change, for a reference person with each of
several medical conditions. Percentages of exhaled sub-
stances, such as Hz, CO, ammonia, acetone, methanol and/or
ethanol, should also be compared with corresponding ref-
erence ranges. Breath can be analyzed using an NS array or
a DMS module.
A body decreases its core temperature by sweating, also
referred to as evaporative cooling. The amount of perspira-
tion lost by evaporative cooling is variable (100-8,000
mL/day), depending upon environmental conditions, age,
gender, genetics, and the two most important factors, fitness
level and body weight. Most of perspiration is water, but
also includes a small amount of solute (0.2-1 percent). The
solute may include Na (0.9 g/L), K (0.2 g/L), Ca (0.015 g/L),
Mg (0.0013 mg/L), Zn (0.4 mg/L), Cu (0.3-0.8 mg/L), Cr
(0.1 mg/L), Fe (I mg/L), Ni (0.05 mg/L), Pb (0.05 mg/L),
minerals, lactate and urea. Normal perspiration is mildly
acidic, with pH lying in a range 4.5-7. Measured values of
one or more of these chemicals, or of the pH, can be
compared against a corresponding reference range after
moderate to vigorous exercise, to estimate which medical
condition(s) is/are present in a target person. Perspiration
can be analyzed using a DMS module or an NS array.
Saliva is approximately 99 percent water and 1 percent
electrolytes, mucus, glycoproteins, enzymes and anti-bacte-
rial compounds. Saliva is super-saturated with selected ions,
which act as a buffer to keep the pH of the mouth within a
reasonable range, normally 6.2-7.4. A person of normal
health will secrete 0.75-1.5 liters of saliva per day. This
secretion decreases to approximately zero during sleep.
Normal ranges for electrolytes found in saliva include Na
(2-21 mmol/L), K (10-36 mmol/L), Ca (1.2-2.8 mmol/L),
Mg (0.08-0.5 mmol/L), Cl (5-40 mmol/L), bicarbonate (25
mmol/L), and phosphate (1.4-39 mmol/L). Measurements
for a target person can be compare with corresponding
reference ranges to estimate which, if any, medical condi-
tions are associated with this person. Saliva can be analyzed
using an NS array or a DMS module.
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Urine, when first excreted, is primarily water (95 percent),
urea ((NH2)—Co (NH2); 9.2 g/L), C12 (1.87 g/L), Na
(1.17 g/L), K (0.75 g/L), creatinine (0.67 g/L), blood urea
nitrogen (BUN), and other dissolved ions and substances.
5 Within two to four hours after excretion, urea partly decom-
poses into NH, and COz molecules, often with an increase
in pH. Measurements of one or more of these urine con-
stituents for a target person can be compared with corre-
sponding reference ranges to estimate which, if any, medical
io condition(s) is/are associated with this target person. Urea
content should be promptly determined, no more than two to
four hours after excretion, and the concentration differences
compared with corresponding reference differences. As
noted above, urea is often a constituent present in perspira-
15 tion. Urine can be analyzed using an NS array or a DMS
module.
The system disclosed here is an integrated package of
several medical diagnosis approaches that can accept and
separate gas and liquid components of body fluids, that can
20 work cooperatively to identify presence of complex combi-
nations of medical conditions, and that can analyze each
component according to the most relevant and efficient
methods available. First and second medical conditions,
estimated to be present in the target person from results
25 provided by the NS array, and/or by the DMS module, may
differ from each other, or these estimated medical conditions
may overlap. Each of these approaches has its own
strengths, limitations, and scope of chemicals whose pres-
ence can be confirmed (or refuted). The individual diagnosis
30 techniques are flexible and can be adapted to identify
medical conditions that were not initially anticipated.
What is claimed is:
1. A method for analyzing body fluids comprising:
35 collecting from a subject a set of body fluids,
inserting the set of body fluids into a compact integrated
analyzer comprising a plurality of analysis devices, the
plurality of analysis devices comprising a nanostruc-
ture (NS) array, a differential mobility spectrometer
40 (DMS), and a biomarker analyzer (BA) where the BA
is a Centrifuge Assisted Bead Sedimentation Bio-
marker Analyzer (CASBA) or a Capillary Action Bio-
marker Analyzer (CABA), and
displaying results of the analyses;
45 wherein each NS array comprises an unfunctionalized NS
and at least three functionalized NSs, each functional-
ized NS being functionalized to produce changes in
discrete electrical parameter values (EPVs) to permit
estimation of at least one concentration value of at least
50 a first chemical,
wherein each DMS is configured to distinguish between
the relative amounts of a first ion associated with a
second chemical and a second ion associated with a
third chemical, the ions being formed by ionizing a
55 portion of a fluid sample being processed through the
DMS,
wherein each BA is configured to determine a blood cell
count and/or to estimate an amount of a biomarker in
the fluid sample being processed through the BA,
60 wherein the set of results comprises the relative amounts,
counts, and/or concentrations determined by each
analysis device, and/or calculated values or conditions
derived from the relative amounts, counts, and/or con-
centrations determined.
65 2. The method of claim 1, wherein the conditions derived
from the relative amounts, counts, and/or concentrations
determined comprise one or more medical conditions asso-
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ciated with particular combinations or ranges of the relative
amounts, counts, and/or concentrations determined.
3. The method of claim 1, further comprising separating
a member of the set of body fluids into a first gas component
and a first liquid component, processing the first gas com-
ponent and the first liquid components separately, and vola-
tilizing the first liquid component prior to processing.
4. The method of claim 3, wherein the separating com-
prises capturing airborne microdroplets.
5. The method of claim 3, wherein volatilizing the first
liquid component forms a second gas component and a first
residual component, and the method further comprises pro-
cessing the residual component through the BA.
6. The method of claim 1, wherein the set of body fluids
comprises a blood sample, and the method further comprises
processing portions of the blood sample through the DMS
and the BA.
7. The method of claim 1, wherein the set of body fluids
comprises a breath sample, and the method further com-
prises processing portions of the breath sample through the
NS array and the DMS.
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8. The method of claim 1, wherein the set of body fluids
comprises a saliva sample, and the method further comprises
processing portions of the saliva sample through the NS
array and the DMS.
5 9. The method of claim 8, wherein the method further
comprises processing portions of the saliva sample through
the BA.
10. The method of claim 1, wherein the set of body fluids
comprises a perspiration sample, and the method further
comprises processing portions of the perspiration sample
10 
through the NS array and the DMS.
11. The method of claim 1, wherein the set of body fluids
comprises a urine sample, and the method further comprises
processing portions of the urine sample through the NS array
is and the DMS.12. The method of claim 1, wherein the set of body fluids
comprises a blood sample, a breath sample, and a saliva
sample.
13. The method of claim 1, wherein the set of body fluids
20 comprises a blood sample, a breath sample, a saliva sample,
and a perspiration or urine sample.
